Latest Content

After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.

Learn why hepatitis B can reactivate during cancer treatment, which therapies increase the risk and how antiviral medicines can help protect liver health.

After her sister’s Hodgkin lymphoma diagnosis, remission and relapse, a caregiver reflects on follow-up care, guilt and finding hope between cancer battles.

After a pancreatic cancer diagnosis upended his life and career, one survivor reflects on treatment, resilience and finding hope more than a decade later.

The American Society of Hematology published 2026 guidelines for adults with myelofibrosis on Oct. 14, 2026, with 10 recommendations on genetic testing, JAK inhibitors, anemia, transplant referral and aspirin.

A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.

Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.

Lower income, later diagnosis and gaps in treatment drove most of the excess deaths among rural patients, according to new research.

The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.

Twenty-four years after breast cancer, one survivor reflects on mammogram anxiety, the relief of clear results and the gratitude of living beyond cancer.

The immunotherapy may allow some patients with a specific genetic subtype of rectal cancer to avoid surgery, radiation and chemotherapy.

In a randomized trial of nearly 100,000 women in Germany, 3D mammography found a larger share of breast cancers at the screening visit, but its 24% lower rate of cancers found between screenings was not statistically significant.

Eileen Carter was told she had two to three years to live after a stage 4 breast cancer diagnosis. A second opinion changed her care.